Pliant_logo_300x300.jpg
Pliant Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
January 02, 2025 08:00 ET | Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, is...
Pliant_logo_300x300.jpg
Pliant Therapeutics to Participate in Upcoming Investor Events
November 21, 2024 08:00 ET | Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel...
Pliant_logo_300x300.jpg
Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024
November 18, 2024 18:00 ET | Pliant Therapeutics, Inc.
INTEGRIS-PSC featured in an oral late breaker presentation SOUTH SAN FRANCISCO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology...
Pliant_logo_300x300.jpg
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
November 07, 2024 16:05 ET | Pliant Therapeutics, Inc.
BEACON-IPF Phase 2b trial on track for full enrollment in the first quarter of 2025 with data anticipated in mid-2026 SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Pliant...
Pliant_logo_300x300.jpg
Pliant Therapeutics to Participate in the Stifel Healthcare Conference
November 06, 2024 08:00 ET | Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that Keith Cummings, M.D., Chief Financial Officer, and Greg Cosgrove, M.D. FCCP,...
Pliant_logo_300x300.jpg
Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting® 2024
October 17, 2024 08:00 ET | Pliant Therapeutics, Inc.
INTEGRIS-PSC to be featured in an oral presentation on Monday, November 18 SOUTH SAN FRANCISCO, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage...
Pliant_logo_300x300.jpg
Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs
October 01, 2024 16:35 ET | Pliant Therapeutics, Inc.
Former Bristol Myers Squibb Global Medical Affairs Lead brings over 25 years of experience to Pliant SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc....
Pliant_logo_300x300.jpg
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 30, 2024 16:45 ET | Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that on September 30, 2024 it granted stock options to purchase an aggregate...
Pliant_logo_300x300.jpg
Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Respiratory Society International Congress 2024
September 10, 2024 08:00 ET | Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel...
Pliant_logo_300x300.jpg
Pliant Therapeutics to Participate in Upcoming Investor Events
August 28, 2024 08:00 ET | Pliant Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel...